U.S., April 4 -- ClinicalTrials.gov registry received information related to the study (NCT06909604) titled 'Al18F-HER2-BCH PET in Breast Patients Treated With Neoadjuvant Therapy' on Dec. 24, 2024.
Brief Summary: To use the molecular PET radionuclide (F-18) labelled HER2 Affibody to evaluate the predictive and prognostic value in breast patients treated with neoadjuvant therapy
Study Start Date: Jan. 01
Study Type: INTERVENTIONAL
Condition:
Breast Cancer
Intervention:
RADIATION: HER2 expression of PET imaging
Evaluate the diagnostic potential of HER2 imaging using 18F-labelled HER2 affibody , evaluate the predictive and prognostic value of HER2 PET imaging in bladder cancer patients treated with neoadjuvant therapy
Recruitment Sta...